Is AOD-9604 safe? what the human trial data actually shows

Last updated 2026-07-24

is AOD-9604 safe for humans, based on actual trial data?

The honest answer is: probably safe in the short term, based on the trials that were run, but the data set is thin and old. The compound went through obesity trials in the 2000s, and the safety signal that came out was reassuring on the surface. The problem is that safety was never really the sticking point. Efficacy was. A 2004 review in Current Opinion in Investigational Drugs summarized the metabolic profile of AOD-9604 as a lipolytic fragment of human growth hormone, designed to retain the fat-metabolizing region of the HGH molecule while dropping the region tied to growth and insulin resistance effects ^[1]. That's the whole idea behind the drug: keep the fat-burning piece, lose the side effects that come with full-length HGH, like joint swelling, insulin resistance, and abnormal tissue growth. What didn't happen is a large, modern, placebo-controlled phase 3 trial with clean, published, peer-reviewed efficacy numbers that beat placebo by a meaningful margin. The trials that exist are described in general pharmaceutical-development literature (the "Gateways to clinical trials" series covering 2003 and 2005) that catalogs compounds moving through development pipelines, AOD-9604 among them ^[2][3][4]. These are tracking-and-summary publications, not full original trial reports with tables you can independently audit. That matters if you're trying to decide whether to trust the safety picture: a compound can look clean simply because nobody ran a trial large enough, or long enough, to find the rare problems. So when someone asks "is it safe," the fair response is: no red flags showed up in what was tested, but what was tested was limited, and the fat-loss benefit that would justify taking on any risk was never solidly demonstrated.

did AOD-9604 actually work for weight loss in clinical trials?

This is the part that gets buried in marketing copy, so let's put it up front: the weight-loss results in AOD-9604's human trials did not separate convincingly from placebo. That is the central finding, and it is why the drug never reached the market as an approved obesity treatment anywhere, including the US, Australia, or the EU. The fragment rationale is genuinely clever on paper. Full-length human growth hormone drives lipolysis (fat breakdown) but also raises blood sugar and can cause insulin resistance and fluid retention with prolonged use. Researchers identified a small region near the C-terminus of the HGH molecule, roughly residues 176 to 191, that appeared responsible for the fat-metabolizing effect without the growth-promoting or blood-sugar-disrupting effects. That fragment is AOD-9604. A 2006 review of obesity drugs in development lists it among the many compounds explored for anti-obesity potential during that era, most of which likewise failed to clear the efficacy bar needed for approval ^[5]. The practical read: mechanism plausibility is not the same as clinical proof. Lots of molecules look good in a lab explanation and then fail to move the needle on an actual bathroom scale in a randomized trial. That's what appears to have happened here. If you want a peptide with a stronger, more recent efficacy record for fat loss, AOD-9604 is not where the strongest data lives. Compare that against approved GLP-1 agents, which have multi-year, multi-thousand-patient trials behind them. AOD-9604 doesn't have anything close to that scale of evidence. If you're trying to understand the mechanism in more depth before deciding anything, our AOD-9604 peptide overview walks through the fragment biology and where the theory came from.

what side effects has AOD-9604 shown in human studies?

Reported issues in the available literature are mild and mostly injection-related: redness, minor swelling, or irritation at the injection site. That tracks with what you'd expect from a small peptide given by injection rather than a growth hormone analog with systemic hormonal effects. What's notably absent from the AOD-9604 profile, based on the mechanism and the reviews describing it, are the classic HGH side effects: joint pain and swelling, carpal tunnel-like symptoms, elevated blood sugar, and insulin resistance. That absence is the entire point of the fragment design, restricting the molecule to the region tied to fat metabolism and removing the region tied to growth-hormone-receptor-mediated effects ^[1]. But here's the honest caveat: absence of reported side effects in short trials from companies developing a drug for approval is not the same as a clean long-term safety record established over years of widespread use, the way we have for approved obesity drugs. Nobody has published a large post-market surveillance data set for AOD-9604 because it never reached that stage of use as an approved medicine. For a fuller rundown of what's actually documented, see AOD-9604 peptide side effects.

is AOD-9604 FDA approved?

No. AOD-9604 has no FDA approval for any indication. You can check this yourself in Drugs@FDA, the FDA's own database of approved drug products, where it does not appear ^[6]. This matters beyond a technicality. FDA approval means a drug went through phase 1 through phase 3 trials with pre-specified endpoints, met a bar for both safety and efficacy, and got manufacturing oversight afterward. None of that applies to AOD-9604. It sits in a much less regulated space: research chemical and compounding markets. On the compounding side, the FDA maintains lists under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act that define which bulk drug substances pharmacies can legally use to compound medications for individual patients [21 U.S.C. 353a] ^[7]. AOD-9604 is not on the 503A bulks list ^[8] or the 503B bulks list ^[9], and it does not appear on FDA's current list of bulk substances nominated for compounding use ^[10]. That's a real regulatory gap, not a minor paperwork issue: it means a state-licensed pharmacy filling AOD-9604 under a compounding framework is operating outside the substances FDA has evaluated and permitted for that purpose.

is AOD-9604 legal to buy and use?

It depends heavily on what you mean by "use." It is generally sold in the US as a research chemical, labeled "not for human consumption," which is a legal workaround that sellers use to avoid drug-marketing regulations under 21 CFR 201.128, the FDA rule defining what counts as an "intended use" that triggers drug-approval requirements ^[11]. That labeling framework creates a strange situation: the product is legal to purchase as a lab chemical, but using it on yourself as a fat-loss aid steps outside what that labeling permits, and there's no FDA-sanctioned pathway making that personal use legal or medically supervised in the way an approved prescription drug is. Some compounding pharmacies offer it under physician oversight, which is a different model: a licensed provider evaluates you, writes an order, and a pharmacy prepares it. That's a more accountable path than an unlabeled vial from an anonymous research-chemical site, since there's a person with a license and an inspection record involved. It doesn't erase the substance's absence from FDA's compounding bulks lists ^[8][9], but it does mean at least one party in the transaction is accountable to a state pharmacy board.

does AOD-9604 show up on a drug test or WADA screening?

A 2013 study in Drug Testing and Analysis tested this directly and found that AOD-9604 does not influence the WADA hGH isoform immunoassay, the test anti-doping labs use to detect growth hormone doping ^[12]. In plain terms: the fragment doesn't trigger a positive on the standard hGH test, because it's structurally different enough from intact growth hormone that the isoform-ratio assay doesn't flag it. That doesn't mean AOD-9604 is untraceable or unregulated in competitive sport. Anti-doping labs have separately built detection methods aimed at peptides generally. A 2014 paper in the Journal of Pharmaceutical and Biomedical Analysis reviewed analytical approaches for catching emerging therapeutics and non-approved drugs, including small peptides, in doping controls ^[13]. A 2014 review in Expert Review of Proteomics covered detection strategies specifically for peptidic drugs, drug candidates, and their analogs in sports doping ^[14], and a 2016 study in the Journal of Separation Science described a method using direct urine injection with liquid chromatography and ion mobility mass spectrometry to screen for peptides under 2 kDa, a size range that includes fragments like AOD-9604 ^[15]. The short version for athletes: not flagging the hGH isoform test isn't the same as being cleared for competition. If you're a tested athlete, treat any unapproved peptide as a doping risk until you've checked its status directly with your sport's anti-doping body.

how does AOD-9604's safety profile compare to other weight-loss peptides?

Here's a side-by-side of where AOD-9604 sits relative to compounds people commonly compare it against. This isn't a ranking of which is "best," it's a comparison of what level of evidence backs each one.

The takeaway from that table isn't complicated. AOD-9604 occupies the weakest evidence tier of the three. It was designed to avoid HGH's downsides, and the safety data that exists suggests it did that reasonably well. But it never generated the efficacy data needed to sit anywhere near approved obesity medicines in terms of trust.

what does the fragment design actually do, and is the theory sound?

The theory is sound as biology; it just didn't translate into a proven clinical result. Growth hormone's fat-metabolizing effects and its growth-promoting, blood-sugar-raising effects are driven by different parts of the molecule. Splitting off just the lipolytic fragment, in theory, gets you fat metabolism without the downsides. The 2004 review in Current Opinion in Investigational Drugs describes this metabolic rationale directly, characterizing AOD-9604 by its specific fat-metabolizing mechanism distinct from the growth-promoting activity of full HGH ^[1]. That's real, published science, and it's not a fringe idea. It's the same logic that's driven a lot of peptide drug development generally. Where it runs into trouble is the gap between plausible mechanism and demonstrated human outcome. A molecule can hit its intended biological target and still not produce a clinically meaningful, statistically separated effect in a randomized trial, for reasons that include dosing, absorption, trial size, or the biological pathway mattering less than the theory predicted. That's the situation AOD-9604 appears to be in. The mechanism story is coherent. The proof that it moves body fat meaningfully more than placebo isn't there in the published record.

is AOD-9604 being studied for anything besides weight loss?

Recent literature has looked at peptides broadly, AOD-9604 included, in contexts outside obesity, mainly orthopaedics and musculoskeletal recovery, though this is early and not the same evidence base as a weight-loss claim. A 2026 paper in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews covered therapeutic peptides in orthopaedics generally, discussing applications, challenges, and future directions across a range of peptide compounds ^[16]. A separate 2026 paper in Sports Medicine reviewed the safety and efficacy of both approved and unapproved peptide therapies used for musculoskeletal injuries and athletic performance ^[17]. Neither of those papers is a dedicated AOD-9604 obesity trial, and citing them to claim AOD-9604 "works" for joint or tendon repair would be overselling what they show. What they do indicate is that peptide research as a field keeps moving, and AOD-9604 gets mentioned in these broader review contexts even though its own dedicated efficacy trial record for fat loss remains weak. If you're specifically weighing AOD-9604 for fat loss rather than any other use, keep that distinction sharp: the orthopaedic literature is a different question with different evidence.

who should avoid AOD-9604 entirely?

A few groups should skip this one without much debate. Pregnant or breastfeeding people, anyone with a history of hormone-sensitive conditions, and tested athletes in sports with strict anti-doping rules all have clear reasons to avoid an unapproved, poorly-evidenced peptide. Tested athletes specifically should know that even though AOD-9604 doesn't trigger the WADA hGH isoform immunoassay ^[12], detection methods for peptides broadly keep advancing ^[13][14][15], and using any unapproved compound carries real career risk regardless of whether today's specific assay catches it. Anyone expecting FDA-approved-drug-level certainty about long-term safety should also sit this one out, because that certainty doesn't exist here. The trials that were run were short, and none of them generated the kind of multi-year safety surveillance data that backs approved obesity medicines.

if you're going to try it anyway, what's the more careful path?

If you've read all of the above and still want to try AOD-9604, the more careful path is provider-reviewed sourcing rather than an anonymous research-chemical vial. That means a licensed provider evaluates your health history, discusses the actual (limited) evidence with you honestly, and a pharmacy fills the order under its own regulatory accountability, even though AOD-9604 sits outside the FDA's 503A and 503B bulks lists ^[8][9]. AOD-9604 Co reviews provider and pharmacy options specifically so you're not guessing at sourcing quality on your own. That's a meaningfully different risk profile than buying from a site with no license, no quality testing disclosure, and no accountable person behind the transaction. Before going further, it's worth reading the dosing and reconstitution details so you understand what you'd actually be committing to: see AOD-9604 dosage, AOD-9604 how to reconstitute, and the AOD-9604 dosage calculator if you want to model out a protocol. And if you're comparing where to source it, AOD-9604 peptide for sale covers what separates a provider-reviewed source from a bargain-bin one.

Frequently asked questions

is AOD-9604 safe for long-term use?

Nobody has good long-term human safety data on AOD-9604, because it never went through the years of post-market surveillance that approved drugs get. Short trials showed mild, mostly injection-site side effects ^[1], but that's a limited window. Treat long-term safety as unproven rather than confirmed either way.

does AOD-9604 actually cause fat loss?

The trial data that exists did not show fat-loss results that convincingly beat placebo ^[1][5]. The fragment's fat-metabolizing mechanism is biologically plausible, but plausible mechanism and proven clinical outcome are two different things, and the second one is missing here.

is AOD-9604 approved by the FDA?

No. AOD-9604 does not appear in Drugs@FDA, the FDA's database of approved drug products ^[12], and it is not on the FDA's 503A or 503B bulk drug substance lists for compounding ^[14][15]. It has no approved medical indication in the US.

will AOD-9604 show up on a doping test?

A 2013 study found AOD-9604 does not influence the WADA hGH isoform immunoassay ^[2], so it doesn't trigger that specific test. But peptide detection methods keep advancing ^[6][10][11], so tested athletes should still treat it as a doping risk, not a loophole.

what side effects does AOD-9604 cause?

Reported effects are mostly mild injection-site reactions like redness or irritation. The classic HGH side effects, joint swelling, elevated blood sugar, insulin resistance, have not shown up in the AOD-9604 literature, consistent with the fragment design excluding the region tied to those effects ^[1].

why isn't AOD-9604 FDA approved if it's safe?

Approval requires proven efficacy, more than an acceptable safety profile. AOD-9604's obesity trials did not show weight-loss results that clearly separated from placebo ^[1][5], so it never met the bar for approval regardless of how clean its short-term safety data looked.

is AOD-9604 legal to buy in the US?

It's typically sold labeled as a research chemical, not for human consumption, under 21 CFR 201.128's framework for intended use ^[17]. That's a legal gray zone for personal use rather than a clear approval. Some compounding pharmacies offer it under provider oversight instead.

how is AOD-9604 different from regular HGH?

AOD-9604 is a small fragment covering roughly the C-terminal region of the HGH molecule tied to fat metabolism, without the growth-promoting, insulin-resistance-linked regions of full-length HGH ^[1]. That's the design rationale, though efficacy for fat loss hasn't been proven in trials.

has AOD-9604 ever completed a phase 3 trial?

There's no published, peer-reviewed phase 3 trial report with clear efficacy endpoints beating placebo. The available record comes largely from development-pipeline summary literature from the mid-2000s ^[7][8][9], not a full modern phase 3 publication.

can AOD-9604 be legally compounded by a pharmacy?

AOD-9604 is not currently on FDA's 503A bulks list ^[14] or 503B bulks list ^[15], the lists that define substances pharmacies can use under those compounding frameworks. That's a real regulatory gap pharmacies and patients should understand before assuming compounded AOD-9604 has the same standing as approved compounded drugs.

is AOD-9604 being researched for anything other than weight loss?

Recent 2026 reviews have discussed peptides broadly, including AOD-9604, in orthopaedic and musculoskeletal injury contexts ^[3][4]. That's separate from its obesity trial history and shouldn't be read as new proof it works for fat loss.

what's a safer alternative to AOD-9604 for fat loss?

Approved GLP-1 receptor agonists have far larger, longer, better-published trial records with FDA-reviewed efficacy and safety data, listed in Drugs@FDA ^[12]. If proven efficacy matters most to you, that class currently has stronger human evidence than AOD-9604 does.

Sources

1. PubMed, Current Opinion in Investigational Drugs (2004), PMID 15134286: AOD-9604 is characterized as a fat-metabolizing HGH fragment distinct from growth-promoting HGH activity; obesity trial fat-loss results did not convincingly separate from placebo
2. PubMed, Drug Testing and Analysis (2013), PMID 24124033: AOD-9604 does not influence the WADA hGH isoform immunoassay used to detect growth hormone doping
3. PubMed, JAAOS Global Research & Reviews (2026), PMID 41490200: Recent review of therapeutic peptides in orthopaedics, applications, challenges, and future directions, discussing peptides including AOD-9604
4. PubMed, Sports Medicine (2026), PMID 41966639: Review of safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance
5. PubMed, Current Opinion in Investigational Drugs (2006), PMID 16625817: Review of obesity drugs in clinical development during the mid-2000s, the era AOD-9604 was being tested for weight loss
6. PubMed, Journal of Pharmaceutical and Biomedical Analysis (2014), PMID 24906629: Analytical approaches exist for detecting emerging therapeutics and non-approved drugs including peptides in doping controls
7. PubMed, Methods and Findings in Experimental and Clinical Pharmacology (2003), PMID 14685303: Gateways to clinical trials pipeline summary tracking compounds in development including AOD-9604
8. PubMed, Methods and Findings in Experimental and Clinical Pharmacology (2003), PMID 14571286: Gateways to clinical trials pipeline summary tracking compounds in development including AOD-9604
9. PubMed, Methods and Findings in Experimental and Clinical Pharmacology (2005), PMID 15834452: Gateways to clinical trials pipeline summary tracking compounds in development including AOD-9604
10. PubMed, Expert Review of Proteomics (2014), PMID 25382550: Detection strategies for peptidic drugs, drug candidates, and analogs in sports doping continue to develop
11. PubMed, Journal of Separation Science (2016), PMID 26578461: Method using direct urine injection, liquid chromatography, and ion mobility mass spectrometry screens for peptides under 2 kDa
12. FDA, Drugs@FDA database: AOD-9604 does not appear as an FDA-approved drug product
13. Cornell Law School, 21 U.S.C. 353a, pharmacy compounding: Federal statute governing pharmacy compounding conditions under Section 503A
14. eCFR, 21 CFR 216.23, the 503A Bulks List: AOD-9604 is not on the FDA's final 503A bulk drug substances list for compounding
15. eCFR, 21 CFR 216.24, the 503B Bulks List: AOD-9604 is not on the FDA's 503B bulk drug substances list for outsourcing facility compounding
16. FDA, bulk drug substances nominated for use in compounding (current list): AOD-9604 does not appear on FDA's current list of nominated bulk substances for compounding
17. eCFR, 21 CFR 201.128, meaning of intended uses: Defines the regulatory concept of intended use that research-chemical labeling attempts to work around